Drugs that contain Fidaxomicin
1. Drug name - DIFICID
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8586551 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jul, 2023
(9 months from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
| US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(4 years from now) | |
| CN102746353A | CUBIST PHARMS LLC | Macro-Cyclic Polymorphic Substance, Composition With This Macro-Cyclic Polymorphic Substance, Usage And Preparation Method Thereof |
May, 2016
(6 years ago) | |
| CN101340919B | CUBIST PHARMS LLC | Method Of Treating Clostridium Difficile Associated Diarrhea |
Dec, 2017
(4 years ago) | |
| CN101340919A | CUBIST PHARMS LLC | Method Of Treating Clostridium Difficile-Associated Diarrhea |
Dec, 2017
(4 years ago) | |
| CN100519757C | CUBIST PHARMS LLC | Preparation Of Tiacumicins |
Jul, 2023
(9 months from now) | |
| CN1688707A | CUBIST PHARMS LLC | Preparation Of Table Hook |
Jul, 2023
(9 months from now) | |
| CN102614207B | CUBIST PHARMS LLC | 18 Membered Macrocyclic Compounds And Analogues Thereof |
Jan, 2025
(2 years from now) | |
| CN102614207A | CUBIST PHARMS LLC | 18-Membered Macrocyclic Compound And Analog Thereof |
Jan, 2025
(2 years from now) | |
| CN101128114B | CUBIST PHARMS LLC | 18 Membered Macrocyclic Compounds And Analogues Thereof |
Jan, 2025
(2 years from now) | |
| CN101128114A | CUBIST PHARMS LLC | 18-Membered Macrocycles Compound And Analogs |
Jan, 2025
(2 years from now) | |
| CN101663312B | CUBIST PHARMS LLC | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof |
Jan, 2028
(5 years from now) | |
| CN101663312A | CUBIST PHARMS LLC | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof |
Jan, 2028
(5 years from now) | |
| EP2070530B1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP1765312A2 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP1765312A4 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP2305245A1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP1765312B1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP2070530A1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP2305244A1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP2305245B1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP2305244B1 | CUBIST PHARMS LLC | Treatment Of Diseases Associated With The Use Of Antibiotics |
May, 2025
(2 years from now) | |
| EP1539977A2 | CUBIST PHARMS LLC | Tiacumicin Production |
Dec, 2026
(4 years from now) | |
| EP1539977A4 | CUBIST PHARMS LLC | Tiacumicin Production |
Dec, 2026
(4 years from now) | |
| EP1539977B1 | CUBIST PHARMS LLC | Tiacumicin Production |
Dec, 2026
(4 years from now) | |
| EP3412678A1 | CUBIST PHARMS LLC | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof |
Jan, 2028
(5 years from now) | |
| EP2125850A1 | CUBIST PHARMS LLC | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, Methods Of Manufacture And Use Thereof |
Jan, 2028
(5 years from now) | |
| EP2125850B1 | CUBIST PHARMS LLC | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, Methods Of Manufacture And Use Thereof |
Jan, 2028
(5 years from now) | |
| EP3412678B1 | CUBIST PHARMS LLC | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, And Methods Of Use And Manufacture Thereof |
Jan, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8586551
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jan, 2024
(1 year, 3 months from now) | |
| US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(4 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
| US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
|
US7906489
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(4 years from now) | |
|
US8859510
(Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(5 years from now) | |
|
US7378508
(Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(5 years from now) | |
|
US7863249
(Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(5 years from now) | |
| US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(11 years from now) | |
|
US9808530
(Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(12 years from now) | |
Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.